Blood Transfusion News
-
BIOtechNOW featured IVS’s participating BIO Innovation Zone
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech ...
-
Quidel Announces Preliminary Revenue for Fourth Quarter 2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”),a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million. COVID-19 ...
-
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to be dosed in third quarter of 2022 Preliminary proof-of-concept data presented at ASH 2021 showed ...
-
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
No adverse events related to investigational SAR445136 were reported All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 ...
-
NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease
The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in response to a targeted solicitation from NIAID aimed at improving ...
-
Reetoo made a wonderful appearance at CACLP
From March 28 to March 30, 2021, the 18th China International Laboratory Medicine and Blood Transfusion Instruments and Reagent Expo was successfully held at Chongqing International Expo Center. Reetoo Biotech carries 7 major types of specimen series products, including vaginal secretion detector, sperm quality analyzer, automatic chromosome microscopic image scanning system, automatic urine ...
-
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum ...
-
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the ...
-
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
Grifols (MCE: GRF, MCE: GRF.P,NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. No additional financing will be required. The closing of the ...
-
Fibralign Announces Strategic Partnership with Terumo
Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema. BioBridge is a sterile implantable biocompatible and biodegradable surgical mesh made of highly ...
-
Grifols continues to reinforce its commitment to all stakeholders as a response to COVID-19
Grifols has adopted a number of measures since the onset of the pandemic in order to respond to the needs of its stakeholders. The company continually monitors the progression of COVID-19, analyzing and evaluating its potential impact on its workforce and operations to guarantee minimal delays or interruptions in our operations as Grifols’ products and services are essential for patients ...
-
Grifols maintains its operational levels and continues to reinforce its commitment to society
Grifols increases its revenues by 12% to EUR 1,293 million The Bioscience Division leads growth, increasing revenues by 13.6% (10.9% cc) to EUR 1,040 million, driven mainly by the demand for strong key proteins, especially with immunoglobulins Diagnostic and Hospital Division revenues remain stable at EUR 168 million (1.4%; -0.3% cc) and EUR 31 million (0.6%; 0.8% cc), respectively. Bio ...
-
Grifols and Shanghai RAAS close their strategic alliance in China
Grifols controls a 26.20% stake in Shanghai RAAS (economic and voting rights) in exchange for a non-majority share on behalf of Shanghai RAAS (45% economic rights and 40% voting rights) in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS) Over the past 35 years, Grifols has increasingly expanded its presence in China, which is currently the company’s third-largest sales ...
-
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
Grifols today announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical ...
-
Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million
Revenue increases 13.6% (9.2% cc) as a result of the sustainable growth strategy, with advances in all divisions and regions Bioscience leads the growth with EUR 3,994 million of revenue (13.6%; 8.9% cc). Diagnostic and Hospital continue to make progress with sales of EUR 734 million (4.5%; 1.1% cc) and EUR 134 million (12.5%; 12.1% cc), respectively. Bio Supplies achieves EUR 267 million in ...
-
Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region
Grifols and the Public Investment Fund of Saudi Arabia (PIF) have executed a non-binding term sheet to build a network of plasma collection centers and other facilities for the production of plasma medicines, including a plasma fractionation plant and a purification plant, in Saudi Arabia. Following definitive agreements being signed, the project would be executed ...
-
Anxin medicine introduces you to the secrets of medical polymer materials
Medical polymer materials for the first time into the line of sight of people in 1949, is the first published the prospect of medical polymer materials, for the first time introduced the use of poly (methyl methacrylate as a person's skull, joint and femoral, using polyamide as the clinical application of surgical suture, since then, usher in rapid development of medical polymer materials, is ...
-
Gauss Raises $20 Million in Series C From Northwell Health Softbank Ventures Korea for AI-Enabled Platform for the Operating Room
Gauss Surgical, an AI-driven healthcare technology company, raised $20 million in Series C funding from Northwell Health and SoftBank Ventures Korea, the global early-stage venture capital arm of SoftBank Group, as well as from the LS Polaris Innovation Fund and seven other leading US health systems. The proceeds of the round will be used to accelerate the adoption of its Triton platform in ...
-
Agilent Technologies presents 2011 manfred donike award for excellence in sports-doping detection to german and swiss researchers
Agilent Technologies, Inc. (NYSE: A) today announced it has presented the 2011 Manfred Donike Award for scientific excellence in sports-doping testing to Simon Beuck and Nicolas Leuenberger. Agilent sponsors this annual award to recognize distinguished scientific contributions in doping analysis. Award winners are scientists who exemplify the spirit and scientific leadership of doping control ...
-
Merck to initiate proof-of-concept study of posaconazole for chronic chagas disease, recognized by WHO as one of the world`s neglected tropical diseases
Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you